Fresh analysis reveals that patients who discontinue new slimming jabs like Wegovy and Mounjaro tend to recover reduced body mass at a significantly accelerated pace than those who end conventional diet and exercise plans.
Published data in a major health publication shows that while obese individuals can lose a large proportion of their body weight while undergoing treatment, the weight returns at an average rate of 0.8 kg per month once they quit.
"Users buying these treatments need to be aware of the risk of quick weight regain when the therapy concludes," stated researcher Dr. Susan Jebb.
This pace of recovery implies a return to pre-treatment weight in about one and a half years.
Comparing Approaches
The analysis, which looked at dozens of studies involving over 9,000 of patients, compared the effects of the injectable medications with other pills.
The team note that people who lose weight through dieting generally see a more gradual creep back—approximately 0.1 kg a month—once they finish.
The Reason for the Fast Rebound
Nutrition scientists believe the way of the jabs explains the accelerated weight return.
These medications mimic a natural hormone called GLP-1, which controls appetite.
"Artificially providing the hormone levels several times higher than normal could lead to the body to produce less of its own natural hormone, and could reduce responsiveness to its effects," said Dr. Adam Collins, a dietetics specialist.
"Stopping of this hormone supplement means appetite is no longer kept in check, making excessive eating much more probable."
An Ongoing Condition?
Medical guidelines advise the injections for people with obesity-related health risks, accompanied by recommended diet and exercise modifications.
A number of clinicians contend that, due to the likelihood of weight regain, the treatment should be considered life-long.
This opinion is reinforced by pharmaceutical companies, who note that the findings "underscore the long-term nature of excess weight," comparing it to managing conditions like hypertension.
User Experiences
Users who have stopped the medication describe a intense resurgence of cravings.
"It was like something flipping and you're instantly extremely hungry," said a patient.
This difficulty is worsened if individuals have not adopted lasting lifestyle or habit changes during therapy.
Growing Interest
Survey data suggest that millions of people in the UK have tried these injections in the last 12 months, with interest continuing to grow.
- Use is greater among females than men.
- The middle-aged demographic shows the highest usage rates.
- A large proportion obtain the drugs through private prescriptions rather than the NHS.
In conclusion, clinicians emphasize that while GLP-1 drugs are effective tools for weight loss, they are not a standalone cure and long-term success hinges on ongoing lifestyle changes.
